Contribution of Macrophage Migration Inhibitory Factor -173G/C Gene Polymorphism to the Risk of Cancer in Chinese Population

  • Wang, Cheng-Di (Department of Respiratory Medicine, West China Hospital, Sichuan University) ;
  • Li, Tai-Ming (Department of Pediatric Surgery, West China Hospital, Sichuan University) ;
  • Ren, Zheng-Ju (Department of Urology, West China Hospital, Sichuan University) ;
  • Ji, Yu-Lin (Department of Respiratory Medicine, West China Hospital, Sichuan University) ;
  • Zhi, Liu-Shou (Department of Respiratory Medicine, West China Hospital, Sichuan University)
  • Published : 2015.06.26


Background: Macrophage migration inhibitory factor (MIF) -173G/C (rs755622) gene polymorphism has been associated with cancer risk. Previous studies have revealed that MIF -173G/C gene polymorphism may increase cancer in the Chinese population, while results of individual published studies remain inconsistent and inconclusive.We performed this meta-analysis to derive a more precise estimation of the relationship. Materials and Methods: We conducted a search on PubMed, Embase, MEDLINE, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Wanfang, Weipu on Dec 31, 2014.Odds ratio (OR) and 95% confidence interval (95% CI) were used to assess the association. A total of eight studies including 2,186 cases and 2,285 controls were involved in this meta-analysis. Results: The pooled results indicated the significant association between MIF -173G/C polymorphism and the risk of cancer for Chinese population (CC + CG vs GG: OR=1.14, 95%CI=1.02-127, pheterogeneity<0.01; P=0.023; CC vs CG+GG: OR=1.12, 95%CI=1.02-1.23, pheterogeneity<001; P=0.017;CC vs GG: OR=1.18, 95%CI=1.04-1.33, pheterogeneity<001; P=0.008; CG vs GG:OR=1.03, 95%CI=0.91-1.15, pheterogeneity<001; P=0.656; C vs G:OR=1.24, 95%CI=1.14-1.25, pheterogeneity<001; P<001). Subgroup analysis showed that in patients with "solid tumors", heterogeneity was very large (OR=0.94,95%CI=0.83-1.06,pheterogeneity=0.044; p=0.297). Within "non-solid tumors", the association became even stronger (OR=6.62, 95 % CI=4.32-10.14, pheterogeneity<0.001; p<0.001). Conclusions: This study suggested that MIF -173G/C gene polymorphism may increase increase cancer in the Chinese population.Furthermore, more larger sample and representative population-based casees and well-matched controls are needed to validate our results.


hage migration inhibitory factor (MIF);cancer;polymorphism;Chinese


  1. Arisawa T, Tahara T, Shibata T, et al (2008). Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. Oncology reports, 19, 223-8.
  2. Babu SN, Chetal G, Kumar S (2012). Macrophage migration inhibitory factor: A potential marker for cancer diagnosis and therapy. Asian Pac J Cancer Prev, 13, 1737-44.
  3. Balkwill F, Mantovani A (2010). Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther, 87, 401-6.
  4. Bloom BR, Bennett B (1966). Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science, 153, 80-2.
  5. Chen W, Zheng R, Zeng H, Zhang S, et al (2015). Annual report on status of cancer in China, 2011. Chin J Cancer Res, 27, 2-12
  6. De Benedetti F, Cristina M, Vivarelli M, et al (2003). Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum, 48, 1398-407.
  7. Ding GX, Zhou SQ, Xu Z, et al (2009). The association between MIF-173 G>C polymorphism and prostate cancer in southern Chinese. J Surg Oncol, 100, 106-110.
  8. Du JZ, Dong YL, Wan GX, et al (2014). Lack of Association between the COMT rs4680 polymorphism and ovarian cancer risk: evidence from a meta-analysis of 3,940 individuals. Asian Pac J Cancer Prev, 15, 7941-5.
  9. Gu S, Wu Q, Zhao X, et al (2012). Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy. Cancer Sci, 103, 1451-59.
  10. Li H, Zang J, Wang P, et al (2012). Gastric cancer susceptibility in gastric cancer relatives: attributable risks of Macrophage migration inhibitory factor promoter polymorphism and Helicobacter pylori. Cytokine, 60, 346-351.
  11. Meyer-Siegler KL, Bellino MA, Tannenbaum M (2002). Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer, 94, 1449-56.
  12. Meyer-Siegler KL, Iczkowski KA, Vera PL (2005). Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC cancer, 5, 73.
  13. Meyer-Siegler KL, Vera PL, Iczkowski KA, et al (2007). Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes and immunity, 8, 646-52.
  14. Ramireddy L, Chen WT, Peng CT, et al (2014). Association Between Genetic Polymorphism of the MIF Gene and Colorectal Cancer in Taiwan. J Clin Lab Anal, 00, 1-7
  15. Ramireddy L, Lin CY, Liu SC, et al (2014). Association study between macrophage migration inhibitory factor-173 polymorphism and acute myeloid leukemia in Taiwan. Cell Biochem Biophys, 70, 1159-65.
  16. Rendon BE, Roger T, Teneng I, et al (2007): Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem, 282, 29910-8.
  17. Tong X, He J, Liu S, et al (2015). Macrophage migration inhibitory factor -173G/C gene polymorphism increases the risk of renal disease: a meta-analysis. Nephrology, 20, 68-76
  18. Vera PL, Meyer-Siegler K L (2011). Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: a meta-analysis. BMC Res Notes, 4, 395
  19. Verjans E, Noetzel E, Bektas N, e al (2009). Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC cancer, 9, 230.
  20. Wu S, Lian J, Tao H, et al (2011). Correlation of macrophage migration inhibitory factor gene polymorphism with the risk of early-stage cervical cancer and lymphatic metastasis. Oncol Lett, 2, 1261-67.
  21. Xue Y, Xu H, Rong L, et al (2010). The MIF -173G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk Res, 34, 1282-86.
  22. Yang HY, Yang SY, Shao FY, et al (2015). Updated assessment of the association of the XRCC1 Arg399Gln Polymorphism with lung cancer risk in the Chinese population. Asian Pac J Cancer Prev, 16, 495-500.
  23. Yuan Q, Wang M, Zhang Z, et al (2012). Macrophage migration inhibitory factor gene -173G>C polymorphism and risk of bladder cancer in southeast China: a case-control analysis. Mol Biol Rep, 39, 3109-15.
  24. Yuan T, Tang C, Chen M, et al (2013). Influence of the human MIF promoter polymorphism on hepatocellular carcinoma prognosis. Genetics and Molecular Research, 12, 6629-35
  25. Zheng CL, Qiu C, Shen MX, et al (2015). Prognostic impact of elevation of vascular endothelial growth factor family expression in patients with non-small cell lung cancer: an updated meta-analysis. Asian Pac J Cancer Prev, 16, 1881-95
  26. Zhu LX, Ho SC, Wong TK (2013). Effectiveness of health education programs on exercise behavior among patients with heart disease: a systematic review and meta-analysis. J Evid Based Med, 6, 265-301.
  27. Ziino O, D'Urbano LE, Benedetti FD, et al (2005). The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia. Leukemia, 19, 2346-7.

Cited by

  1. ) as potential biomarker for early-stage cervical cancer vol.43, pp.3, 2017,
  2. Macrophage Migration Inhibitory Factor -173 G/C Polymorphism: A Global Meta-Analysis across the Disease Spectrum vol.9, pp.1664-8021, 2018,